ERBB2 and breast carcinoma: This study aimed to develop a novel method to automatically analyze HER2 intratumoral heterogeneity (ITH) and to clarify the clinicopathological characteristics and prognosis of patients with breast cancer with HER2 ITH (Figure S1).